Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
12
Not yet recruiting, industry sponsors, Psychiatry, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed482
12 trials
Showing 1 to 12, recently updated first.
- Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult ParticipantsNot yet recruiting
Neurelis, Inc.Industry
NCT07921966 · 24 participants (planned) · Start Oct 16, 2026 · Primary completion Jan 14, 2027
Drug: NRL-1004 2.5 mg; ZYPREXA IM 10mg and 3 more · For: Healthy Adult Participants
- MLS101 Study in PMDDNot yet recruiting
MycoMedica Life Sciences PBCIndustry
NCT07818720 · 32 participants (planned) · Start Dec 2026 · Primary completion Sep 2027
Drug: MLS101 psilocybin; Placebo capsules · For: Premenstrual Dysphoric Disorder ( PMDD); PMDD
- Phase I Trial of HHK101 in Patients With SchizophreniaNot yet recruiting
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.Industry
NCT07815210 · 88 participants (planned) · Start Nov 15, 2026 · Primary completion Oct 31, 2028
Drug: HHK101-Single Dose 1; HHK101-Single Dose 2 and 6 more · For: Schizophrenia
Sites: Changsha, China; Xi'an, China; Shanghai, China · 4 sites in all
- Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use DisorderNot yet recruiting
Clive MichelsenIndustry
NCT07871877 · 60 participants (planned) · Start Jul 1, 2027 · Primary completion Jan 31, 2029
Drug: Ibogaine Hydrochloride; Extended-release naltrexone injection, 380 mg and 2 more · For: Opioid Use Disorder; Opioid Withdrawal; Substance Use Disorders
Sites: Basalt, Colorado
- A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398Not yet recruiting
Shanghai Zhongze Therapeutics Co., Ltd.Industry
NCT07626034 · 9 participants (planned) · Start Aug 2026 · Primary completion Oct 2027
Drug: SIPI6398 Tablets · For: Schizophrenia Disorder
- A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult SubjectsNot yet recruiting
Jiangxi Kvvit Pharmaceutical Co., Ltd.Industry
NCT07585383 · 66 participants (planned) · Start May 19, 2026 · Primary completion Nov 2026
Drug: KR23248; Matching Placebo · For: Schizophrenia
BioLite, Inc.Industry
NCT03833206 · 12 participants (planned) · Start Jan 15, 2027 · Primary completion Feb 28, 2028
Drug: PDC-1421 Capsule · For: Major Depressive Disorder
Sites: Los Angeles, California
- Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic FunctionNot yet recruiting
Beijing Union Pharmaceutical Factory LtdIndustry
NCT07457190 · 24 participants (planned) · Start Mar 2026 · Primary completion Aug 2026
Drug: Buagafuran · For: Generalized Anxiety Disorder
Sites: Beijing, China
- First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 InjectionNot yet recruiting
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.Industry
NCT07334249 · 80 participants (planned) · Start Dec 23, 2025 · Primary completion Jun 30, 2026
Drug: SP-101 injection; Placebo · For: Major Depressive Disorder, Healthy Volunteer
Sites: Shanghai, China
- Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic InsomniaNot yet recruiting
Nyree PennIndustry
NCT06644573 · 100 participants (planned) · Start Nov 1, 2025 · Primary completion May 1, 2026
Drug: Diprivan (propofol), Astra-Zeneca · For: Chronic Insomnia; Sleep Deprivation; REM Behavior Disorder and 34 more
Sites: Aventura, Florida
- A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017Not yet recruiting
Luye Pharma Group Ltd.Industry
NCT06980207 · 40 participants (planned) · Start May 2025 · Primary completion Oct 2025
Drug: LY03017; LY03017-Placebo · For: Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis; Hallucinations and Delusions Associated With Parkinson Disease Psychosis; Negative Symptoms of Schizophrenia
Sites: Shanghai, China
- Effect of Food and Age on the Pharmacokinetics of LY03017Not yet recruiting
Luye Pharma Group Ltd.Industry
NCT06793995 · 26 participants (planned) · Start Feb 2025 · Primary completion Oct 31, 2025
Drug: LY03017; LY03017 · For: Alzheimer's Disease Psychosis; Parkinson Disease Psychosis; Negative Symptoms of Schizophrenia
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.